Performance of Endobronchial Ultrasound-Guided Cryobiopsy in Diagnosing Thoracic Disorders and Its Role in Next-Generation Sequencing for Non-Small-Cell Lung Cancer.

Background

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an established procedure for diagnosing thoracic diseases and staging of lung cancers. However, some limitations of cytology specimens from EBUS-TBNA include small sample size, low tumour cellularity, necrosis and specimen contamination. Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBMC) is a promising alternative that provides a larger histology specimen which may improve diagnostic accuracy and molecular testing. This study is aimed at evaluating the benefits of EBUS-TBMC over EBUS-TBNA, focusing on improving next-generation sequencing (NGS) success rates, and assessing its efficacy and safety in a real-world setting.

Methods

Data from 203 patients (99 underwent EBUS-TBNA and 104 underwent EBUS-TBMC) were retrospectively traced and analysed using descriptive statistics.

Results

The overall diagnostic yield was significantly higher for EBUS-TBMC (90.38%) than that for EBUS-TBNA (67.68%; p < 0.001). For heterogeneous lesions, the diagnostic yield was 92.31% for EBUS-TBMC and 69.44% for EBUS-TBNA (p = 0.011). For non-small-cell lung cancer (NSCLC), EBUS-TBMC specimens demonstrated higher overall tumour cellularity (65% vs. 30%; p < 0.001) and better success in detecting driver alterations through NGS (85.36% vs. 61.90%; p = 0.035). The median procedure duration was shorter for EBUS-TBMC (22 vs. 32 min; p < 0.001), and the complication rates were comparable between the two techniques. These findings suggest that EBUS-TBMC offers additional diagnostic advantages over EBUS-TBNA for heterogeneous lesions and significantly facilitates the acquisition of cell-rich specimens for NGS testing.

Conclusion

EBUS-TBMC increases the overall diagnostic yield of mediastinal diseases. EBUS-TBMC provides cell-rich histology specimens with high tumour content, facilitating NGS testing in the management of NSCLC.